structures were preferentially lost. To check the second possibility, we correlated a database of cancer CNVs35and TAD boundaries in normal B cells (GM12878). We found that in normal B cells, the average insulation score at the myeloma CNV breakpoints was also lower than that in the ...
Education Lab | CME | This monograph discusses new agents that are being introduced for relapsed/refractory multiple myeloma and the role these agents are likely to play when they become commercially available in the United States. Optimal induction therapy is also reviewe...
I eventually searched for the right type of cancer, learning that Myeloma can be present in your kidneys, blood and bones. This explained why the doctors were going to send me for an x-ray. In the x-ray they were looking for holes (or lytic lesions) in my bones, which would support ...
Multiple myeloma (MM) remains an incurable hematological malignancy disease characterized by the progressive dysfunction of the patient’s immune system. In this context, immunotherapy for MM has emerged as a prominent area of research in recent years. Various targeted immunotherapy strategies, such as...
Chemotherapyis treatment withcancer-fightingdrugs. Because these medicines go into your bloodstream and can reach all parts of your body, they’re a good choice to destroy myeloma cells. You might get chemotherapy as a shot in a vein or take it in pill form. ...
Discover KYPROLIS®, a multiple myeloma treatment option for people who have already received 1 or more previous treatments. See Full Safety & Prescribing Info.
The established interaction between multiple myeloma cells and bone marrow microenvironment components provides malignant cells with various survival, growth and drug resistance signals. As a new concept, identification of miRNAs and their related gene/protein targets, signaling molecules and pathways in the...
Multiple myeloma (MM) is an incurable cancer of terminally differentiated plasma cells that proliferate in the bone marrow. miRNAs are promising biomarkers for risk stratification in MM and several miRNAs are shown to have a function in disease pathogene
Cancer cells are well-known for their capacity to adapt their metabolism to their increasing energy demands which is necessary for tumor progression. This is no different for Multiple Myeloma (MM), a hematological cancer which develops in the bone marrow
The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown. In evaluating cellular energetics and metabolism of t(11;14) and non-t(11;14) MM, we determine that venetoclax-sensitive myeloma ...